Medicare AdvantagePrior AuthMedium impact
Ruxolitinib products (Jakafi, Jakafi XR) (Revised)
Humana·Hematology, Oncology, Internal Medicine·Medicare Advantage
Effective date
Jun 24, 2026
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its prior authorization policy for Ruxolitinib products (Jakafi, Jakafi XR) effective June 24, 2026. The policy maintains coverage for four indications: myelofibrosis (intermediate/high-risk per IPSS), polycythemia vera (after hydroxyurea failure/intolerance), steroid-refractory acute GVHD, and chronic GVHD (after prior systemic therapy failure). Key requirement: all members with prior disease progression on ruxolitinib are excluded from coverage.
Action Required
By June 24, 2026: Billing and prior authorization teams must update internal policy documentation and authorization software to reflect the revised Ruxolitinib coverage criteria. (1) When processing Jakafi or Jakafi XR prior auth requests, verify member meets disease-specific criteria: for myelofibrosis, confirm IPSS risk category (intermediate-2, high, or symptomatic intermediate-1/low); for polycythemia vera, confirm failure/intolerance to hydroxyurea; for aGVHD, confirm steroid-refractory diagnosis; for cGVHD, confirm prior systemic therapy failure. (2) Apply the universal exclusion: deny authorization if member has experienced disease progression while on any prior ruxolitinib product. (3) Alert clinical reviewers to request NCCN MPN-SAF and MPN-SAF-10 documentation at baseline and ongoing therapy for myelofibrosis cases. (4) Update authorization templates to require monotherapy verification (excludes supportive agents). Failure to apply these criteria will result in claim denials and potential medical necessity denials on appeal.